来自WRAPSODY动脉静脉接入效率 (WAVE) 试验的随机控制臂的一年临床结果
Mahmood K Razavi1, Saravanan Balamuthusamy2, Angelo N Makris3
1St. Joseph Heart and Vascular Center, Orange, California, USA.
Journal of vascular and interventional radiology : JVIR
|February 18, 2026
概括
与皮肤透光血管塑造术 (PTA) 相比,WRAPSODY®细胞不透内膜假体 (CIE) 在血液透析患者中显著改善了血管通道通透性. 在12个月后,CIE治疗导致了更高的穿透率和更少的重新干预.
科学领域:
- 血管外科 血管外科
- 腎臟病學 (nephrology) 是一種醫學專業.
- 干预性放射学 干预性放射学
背景情况:
- 血管接入狭窄是血液透析患者的常见并发症,导致接入失败和增加发病率.
- 保持足够的动脉静脉 (AVF) 穿透性对于有效的血液透析治疗至关重要.
研究的目的:
- 评估WRAPSODY®细胞不透内置假体 (CIE) 的12个月疗效和安全结果,与AVF狭窄患者的皮肤透光血管造形术 (PTA) 相比.
- 在WAVE试验的随机控制臂中评估目标损伤初级通透性 (TLPP) 和接入电路初级通透性 (ACPP).
主要方法:
- 一项前性的多中心随机受控试验 (WAVE试验),涉及245名患有AVF狭窄的血液透析患者.
- 患者被随机分配1:1接受WRAPSODY® CIE或PTA治疗.
- 在12个月内测量的关键结果包括TLPP,ACPP,再干预率,设备相关事件和严重不良事件.
主要成果:
- 在12个月后,与PTA相比,WRAPSODY® CIE的TLPP (69.4%对38.5%,p<0.0001) 和ACPP (56.4%对31.1%,p=0.0002) 显著更高.
- 用CIE治疗的患者对于目标病变 (0.50对1.08,p<0.0001) 和接入电路通透性 (1.08对1.70,p=0.001) 需要显著减少重复干预.
- 与设备相关的事件与CIE较低 (2.9%与9.5%,p=0.049),严重不良事件没有显著差异.
结论:
- WRAPSODY® CIE在延长血管通道通透性方面提供了卓越的性能,用于血液透析患者的静脉外流电路狭窄.
- 这些发现为管理AVF狭窄症的临床医生提供了有价值的证据,支持使用CIE以改善长期访问结果.
相关概念视频
01:23Peripheral Artery Disease V: Postoperative Nursing Management
431
During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...
431
01:26Peripheral Artery Disease IV: Nursing Management
405
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
405
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
472
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
472
01:24Hemodialysis II: Procedure and Complications
1.1K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.1K
01:25Hemodialysis I: Introduction
2.0K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
2.0K